Priothera Limited, a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies has announced that it has closed a Series A financing round of €30 million led by Fountain Healthcare Partners. Other investors that participated in the funding round include HealthCap, Tekla Capital Management and EarlyBird Venture Capital. Priothera…